TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

L Paz-Ares et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.